Menopause hormone replacement therapy is medical treatment to replace estrogen, and sometimes progesterone, following menopause, addressing symptoms like hot flashes, sleep disruption, and bone density loss. This is a field reshaped by one landmark study in 2002, then reshaped again by that same study's later re-analysis, worth understanding the actual sequence of events rather than relying on outdated impressions from either era alone.
- The WHI study (2002) reported increased breast cancer and cardiovascular risk, causing sharp prescription drops.
- Later re-analysis found the original study population mostly started therapy years after menopause onset.
- This gave rise to the "timing hypothesis," risk may differ by when therapy starts relative to menopause.
- Remains an individualized medical decision, not a blanket reassurance.
What the WHI found, and what the re-analysis changed
Hormone therapy before 2002
Hormone therapy was widely prescribed, including for cardiovascular prevention, largely on the strength of observational studies showing lower heart disease rates among users. Those studies had a structural problem recognized later: women who took HRT were healthier, wealthier and more engaged with healthcare than those who didn’t.
The 2002 result and its reception
The Women's Health Initiative was the large randomised trial designed to confirm the benefit. Its combined estrogen-plus-progestin arm was stopped early on findings of increased breast cancer, stroke and cardiovascular events. Prescribing collapsed internationally within months, and a generation of women stopped or never started treatment.
The WHI was a large randomised trial of hormone therapy in postmenopausal women. The combined estrogen-plus-progestin arm was stopped early after an interim analysis showed increased breast cancer, alongside increased stroke and blood clots. Coverage was extensive and prescribing fell dramatically within months, worldwide.
Two features of the trial design received far less attention at the time. The average participant was in her early sixties, more than a decade past menopause. And the estrogen-only arm, given to women who had had a hysterectomy, didn’t show the same breast cancer signal.
The timing hypothesis
Later re-analysis by age group found that risk and benefit differed substantially depending on how long after menopause treatment began. Women starting near the menopausal transition showed a more favourable profile than those starting years later. The proposed mechanism is that estrogen acts differently on healthy versus already-atherosclerotic vessels, so starting after plaque has developed produces a different result than starting before.
This remains a hypothesis supported by subgroup and observational data rather than a definitive finding, and subgroup analyses warrant caution. It is nonetheless the reason current guidance distinguishes by timing where the 2002 reaction didn’t.
Later, more detailed re-analysis of the original Women's Health Initiative data revealed an important nuance the initial headline findings hadn't fully captured, the study population was predominantly women starting hormone therapy many years after menopause onset, often in their 60s and 70s, rather than closer to the menopause transition itself. Subsequent research examining risk by timing found that women starting therapy closer to menopause onset showed a meaningfully different, generally more favorable risk profile than the older, later-starting population the original headline findings were based on, giving rise to what's now called the "timing hypothesis" in this field.
- Average age was 63. Participants were on average more than a decade past menopause, which isn’t when hormone therapy is typically initiated in practice.
- Results differed sharply by age. Women starting within ten years of menopause showed a considerably more favourable risk profile than those starting later, giving rise to the timing hypothesis: that hormone therapy may be protective when begun before substantial arterial change and harmful afterwards.
- The estrogen-only arm differed. In women who had had a hysterectomy, estrogen alone didn’t show the same breast cancer signal, implicating the progestin component.
- Formulation and route matter. Transdermal estrogen appears to carry lower clot risk than oral, because it avoids first-pass hepatic metabolism.
What varies between women, and why blanket statements fail
- Formulation. Oestrogen alone versus combined with a progestogen carries different risk, and the type of progestogen appears to matter.
- Route. Transdermal estrogen appears to carry lower clot risk than oral, since it avoids first-pass liver metabolism.
- Dose and duration. Both influence the balance, and lower doses are now more commonly used than in the WHI.
- Personal history. Prior breast cancer, clotting disorders and cardiovascular disease change the calculation entirely.
The established benefits are real: relief of vasomotor symptoms, improved sleep, treatment of genitourinary symptoms, and reduced fracture risk. Whether they outweigh the risks is genuinely individual, which is an unsatisfying answer and the correct one.
The timing hypothesis doesn't mean hormone therapy is now uniformly safe or appropriate for every woman, it means risk profiles appear to differ meaningfully by individual factors, timing relative to menopause onset, personal and family health history, specific formulation and route of administration, making this an individualized medical decision that requires a knowledgeable doctor's guidance rather than either the blanket avoidance common in the years following 2002 or an assumption of blanket safety based on the more recent re-analysis.
What is genuinely still open
The timing hypothesis is well supported but not proven by a trial designed to test it directly. Absolute risks are small and differ by individual history, so the same evidence supports different decisions for different women. And the reasonable duration of treatment remains contested.
This is why the honest answer is that it is an individual decision made with a clinician who knows your history, rather than a general recommendation in either direction. It is also a case study in how a single trial's population can shape practice for two decades.
Few areas of medicine have reversed twice in twenty years. The sequence is worth following, because the current position only makes sense in light of how the earlier one was formed.
Few trials have reshaped clinical practice as abruptly as the Women's Health Initiative. Understanding what it found, and what it didn’t, explains why advice on this subject has moved twice in twenty years.
Then and now
| Period | Prevailing View |
|---|---|
| Pre-2002 | Widely prescribed, viewed favorably |
| Post-WHI (2002 onward) | Sharp decline, widespread concern |
| After timing hypothesis re-analysis | More nuanced, individualized risk assessment |
How the position shifted between 2002 and current guidance. The change reflects re-analysis of the same trial rather than new trials.
Why the advice keeps moving
The framing swings between outdated 2002-era alarm and an oversimplified “it is totally safe now,” missing the nuance the timing hypothesis introduced.
The current picture depends heavily on when treatment starts relative to menopause. That is why blanket advice in either direction misrepresents what the evidence shows.
This is an individual medical decision made with a doctor who knows your history. The markers tracked here matter either way, whichever decision you reach.
The app tracks the markers relevant regardless of your hormone therapy decision, no position taken.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- Rossouw JE, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women (Women's Health Initiative). JAMA, 2002. The original trial.
- Manson JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017. The long-term follow-up.
- The North American Menopause Society. The 2022 Hormone Therapy Position Statement. Source of the timing hypothesis framing.
Frequently asked
Why did hormone therapy use drop in the early 2000s?
The WHI study (2002) reported increased breast cancer and cardiovascular risk, causing sharp prescription declines.
How has interpretation changed since?
Re-analysis found risk differs by timing relative to menopause, giving rise to the "timing hypothesis."
Is it now considered safe for everyone?
No, it remains a genuinely individualized decision requiring a doctor's guidance.
What symptoms does HRT actually treat?
Most reliably, vasomotor symptoms such as hot flushes and night sweats, along with the sleep disruption that follows them, and genitourinary symptoms. These are the indications with the strongest and least contested evidence behind them.
Does HRT cause breast cancer?
The honest answer is that risk varies by preparation, duration, age at initiation and individual history, which is exactly why blanket statements in either direction are unhelpful. It is a genuine consideration to weigh with a clinician rather than a settled yes or no.
What is the timing hypothesis?
The proposal that starting hormone therapy near the onset of menopause carries a different risk-benefit profile than starting many years later. It emerged from re-analysis of the original trial data by age group and reshaped prescribing again.
Are there non-hormonal options for hot flushes?
Yes, several exist including non-hormonal prescription options, and they matter for people who can’t or prefer not to take hormones. Which is appropriate depends on personal history and is a discussion for a clinician.
Does HRT protect against osteoporosis?
It reduces fracture risk, and this is one of its better-established effects. Whether that alone justifies treatment depends on your baseline bone density and what other options are available to you.